GLP-1 Weight Loss Eligibility: Clinical Criteria & Biomarkers

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are generally prescribed for adults with a BMI of 30 kg/m² or higher, or a BMI of 27-29.9 with weight-related conditions such as type 2 diabetes, hypertension, or cardiovascular disease. Qualification requires a comprehensive clinical evaluation by a qualified healthcare provider.

Beyond standard BMI and comorbidity criteria, individual metabolic factors—including glucose regulation, inflammatory markers, and genetic predispositions in peptide signaling pathways—may help provide context for a more personalized treatment approach. Understanding your baseline health profile supports a more informed conversation with your provider about eligibility and realistic expectations.

Standard Clinical Eligibility Criteria for GLP-1 Medications

The FDA-approved indications for GLP-1 receptor agonists include chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI 27–29.9) with at least one weight-related condition. Weight-related conditions include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease.

Providers also consider medication history, kidney function, thyroid status, and personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Age, concurrent medications, and gastrointestinal tolerance are additional factors in the eligibility assessment. No single criterion determines candidacy; comprehensive evaluation is required.

Metabolic Biomarkers That Support Eligibility Conversations

Beyond BMI, biomarkers such as fasting glucose, HbA1c, lipid profile, liver function, and inflammatory markers (e.g., hsCRP) help providers assess metabolic health and predict potential treatment benefit. These biomarkers provide objective context for the underlying metabolic dysregulation that GLP-1 therapy addresses.

Biomarker Category	Clinical Relevance to GLP-1 Eligibility
Glycemic Control (Fasting Glucose, HbA1c)	Identifies insulin resistance and diabetes risk; helps determine if glycemic benefit aligns with weight loss goals.
Lipid Profile (Total, LDL, HDL, Triglycerides)	Reflects cardiovascular risk; GLP-1 therapy may improve triglyceride and cholesterol levels in some patients.
Inflammatory Markers (hsCRP, IL-6)	Elevated inflammation correlates with metabolic syndrome; may predict responsiveness to GLP-1-mediated anti-inflammatory effects.
Kidney Function (eGFR, Creatinine)	GLP-1 drugs require dose adjustment or monitoring in moderate-to-severe renal impairment; essential for safety screening.
Liver Function (ALT, AST, GGT)	Non-alcoholic fatty liver disease is common in obesity; GLP-1 therapy may improve hepatic steatosis in eligible patients.

Genetic Predispositions in Peptide Pathways and Treatment Context

Certain genetic variants in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), FTO, and melanocortin 4 receptor (MC4R) genes influence appetite regulation, energy expenditure, and metabolic response to GLP-1 therapy. Variations in these pathways may contribute to differences in how individuals respond to treatment.

PlexusDx Precision Peptide Genetic Test examines key predispositions in these peptide signaling pathways. This information may help provide context about underlying metabolic architecture and should be interpreted with a qualified healthcare provider to support a more individualized treatment conversation—not to predict exact medication response.

Medical Contraindications and Safety Considerations

Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe hypersensitivity to the drug, and ongoing pancreatitis. Relative contraindications include severe renal impairment, uncontrolled hypertension, and certain psychiatric medications that may interact with GLP-1 effects on appetite and mood.

Pregnancy, breastfeeding, and planned surgery require provider assessment before initiating therapy. Patients with a history of diabetic retinopathy should be monitored closely, as rapid glucose lowering may temporarily worsen vision. A thorough medication review and baseline health assessment are essential to ensure safe candidacy.

How PlexusDx Supports a More Personalized Approach

The PlexusDx Precision Peptide Genetic Test examines predispositions in core peptide pathway genes (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that influence appetite signaling, satiety response, and metabolic rate. These genetic factors may help provide context about individual metabolic architecture and how GLP-1 mechanisms might align with your physiology.

Understanding your genetic predispositions in peptide pathways does not predict exact medication response or guarantee treatment success. However, this information can support a more informed conversation between you and your provider about why GLP-1 therapy may fit into your overall metabolic profile and help identify personalized dosing or adjunctive strategies.

PlexusDx offers the Precision Peptide Genetic Test as a $99 add-on to any product order, or $298 standalone. Combined with compounded GLP-1 options (semaglutide, tirzepatide, or microdose protocols starting at $129/month), a genetic assessment may support a more thoughtful, data-informed approach to eligibility and treatment planning with your provider.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.